Inoviq Ltd · ASX:IIQ
Inoviq — Investor Presentation (June 2024)
38 slides from Inoviq's investor presentation, Jun 12, 2024
Slide 1: Investor update: Next-generation diagnostics and therapeutics
Investor update For personal use only June 2024 Next-generation diagnostics and therapeutics ASX: IIQ
Slide 2: Contents
Contents For personal use only Important Notice & Disclaimer p3 INOVIQ Overview p4 Exosome Platform p7 SubB2M Cancer Diagnostics p14 Catalysts & Transaction Summary p18 Appendices & Risks p25 2
Slide 3: Important Notice & Disclaimer
Important Notice & Disclaimer For personal use only The following notice and disclaimer applies to this investor presentation (Presentation or document) and you are therefore advised to read this carefully Prospective investors should be aware that certain financial data that may be included in this
Slide 4: INOVIQ Overview | Next generation diagnostics and therapeutics
INOVIQ Overview | Next generation diagnostics and therapeutics For personal use only Financial information (ASX:IIQ) $ Ordinary shares1 92,018,702 Exosome Disruptive Products Unlisted options1 8,955,756 powered technology in market 52-week H/L1 A$0.94-0.465 Next-gen exosome Proprietary exosome Exoso
Slide 5: Core Technologies | Research tools, diagnostics and therapeutics
Core Technologies | Research tools, diagnostics and therapeutics For personal use only Strategic Focus Core Technologies Exosome Platform SubB2M Technology Next-generation exosome diagnostics and therapeutics NETs immunoaffinity, magnetic Proprietary neu5Gc probe for bead-based EV isolation for canc
Slide 6: Products & pipeline
Products & pipeline | Multi-stage diagnostics and therapeutics portfolio For personal use only TECHNOLOGY RESEARCH TOOLS INDICATION USE DISCOVERY VERIFICATION VALIDATION IN-MARKET Exosomes EXO-NET Multiple Pan-EV Capture RUO Exosomes NEURO-NET Neurology Brain Derived-EV Capture RUO Exosomes TEXO-NET
Slide 7: Exosome Platform
Exosome Platform For personal use only “Exosomes … could become Research Tools the next frontier in Diagnostics biotherapeutics” Vice President, Lonza Therapeutics “Exosome technology is becoming a mega-trend in the market” CEO, ExoCoBio 7
Slide 8: Exosomes | Significant diagnostic and therapeutic potential
Exosomes | Significant diagnostic and therapeutic potential For personal use only • Exosomes are released by all cells and perform key roles in intercellular communication, immune regulation and disease progression: DNA ➢ Exosomes carry molecular cargo (DNA, RNA, proteins and lipids) that act as RNA
Slide 9: EXO-NET | Exosome isolation products in-market and generating revenue
EXO-NET® | Exosome isolation products in-market and generating revenue For personal use only Best-in-class EXO-NET pan-exosome capture tool (research use only) in-market and surface generating revenue antigens Enables biomarker discovery and diagnostic development exosome Magnetic Core antibodies Of
Slide 10: NEURO-NET | Isolation of brain-derived exosomes
NEURO-NET | Isolation of brain-derived exosomes For personal use only Custom NEURO-NET exosome capture tool for isolation of brain-derived exosomes Designed using proprietary antibody combination that isolates exosomes secreted from brain cells (neurons, microglia, oligodendrocytes & astrocytes) Exo
Slide 11: EXO-NET | Commercial partnerships driving revenue
EXO-NET | Commercial partnerships driving revenue For personal use only Supply and distribution agreement for EXO-NET products worldwide1 Apr 2024 Leading provider of innovative technologies, tools and technical support to the global life sciences industry. Based in US and generating revenues of US$
Slide 12: Lead exosome diagnostic | Ovarian Cancer screening test
Lead exosome diagnostic | Ovarian Cancer screening test For personal use only • #8 cancer in women & deadliest gynaecological cancer • 314k new cases of ovarian cancer worldwide pa1 Development Path Ovarian Cancer • 0.25% of population has Hereditary Breast and Ovarian Cancer syndrome2 Feasibility C
Slide 13: Exosome therapeutics | Targeting solid tumours
Exosome therapeutics | Targeting solid tumours (discovery-stage) For personal use only Engineered Exosome Isolation & Enrichment • INOVIQ is developing weaponised exosomes CAR-NK cells release 150 4×10 9 engineered to target and treat solid tumours number of particles weaponized exosomes total prote
Slide 14: SubB2M Cancer Diagnostics
SubB2M Cancer Diagnostics For personal use only SubB2M tests for detection and monitoring of cancer neuraminic acid (neu5Gc) 14
Slide 15: SubB2M tests for Cancer Monitoring
SubB2M tests for Cancer Monitoring For personal use only INOVIQ is developing non-invasive, earlier and more accurate cancer monitoring tests US$6.1b Breast and Ovarian Cancer diagnostics market Breast Cancer Ovarian Cancer • #1 cancer in women • #8 cancer in women, deadliest gynaecological cancer •
Slide 16: SubB2M Breast Cancer clinical data | Outperformed leading CA15-3 test
SubB2M Breast Cancer clinical data | Outperformed leading CA15-3 test For personal use only Clinical Validation Study (2023)1 SubB2M CA15-3 vs Leading Existing Test Retrospective, case-control, clinical validation study (n=483) Breast Cancer SubB2M Roche ✓ Detected all stages of breast cancer with h
Slide 17: Path-to-Market for SubB2M Breast & Ovarian Cancer monitoring tests
Path-to-Market for SubB2M Breast & Ovarian Cancer monitoring tests For personal use only • SubB2M BC monitoring study Activity CY2024 CY2025 CY2026 successfully completed Feb-24 Assay Development • Engagement with potential US clinical Analytical validation laboratory partners to commercialise Clini
Slide 18: Catalysts & Transaction Summary
Catalysts & Transaction Summary For personal use only 18
Slide 19: Summary | Positioned for growth
Summary | Positioned for growth For personal use only Proprietary exosome platform with multiple research, diagnostic and therapeutic applications Commercial partners secured for EXO-NET research tools to drive revenue growth Fee-for-service revenues from high-throughput EXO-NET exosome isolation, b
Slide 20: Future milestones
Future milestones For personal use only CY 2024 CY 2025 ✓ EXO-NET Supply & Distribution Agreement with Promega ⚫ Commence exosome diagnostic development for Exosome program ⚫ Exosome diagnostic agreement Alzheimer’s Disease ⚫ NEURO-NET validation data ⚫ Commence EXO-OC test clinical validation for o
Slide 21: Capital Raising Overview
Capital Raising Overview For personal use only • The Company has raised A$7.0 million via a placement to sophisticated and professional investors (Placement): o Approximately 14 million new Shares (representing approximately 15.2% of IIQ’s existing issued share capital) and 7 million new Options to
Slide 22: Use of Funds
Use of Funds For personal use only • Funds raised will be used to advance commercialisation of EXO-NET research tools and SubB2M diagnostics, progress development of pipeline diagnostics and expedite research of high-value cancer therapeutics • Enables the company to progress its pipeline and bring
Slide 23: Capital Raising | Placement & SPP
Capital Raising | Placement & SPP For personal use only Event Date Trading halt commences Friday, 7 June 2024 Placement opens 7pm (Sydney time) Record date for SPP Tuesday, 11 June 2024 Announcement of Placement and SPP and Options Wednesday, 12 June Recommencement of trading 2024 Settlement of Plac
Slide 24: International Offer Restrictions
International Offer Restrictions For personal use only This document does not constitute an offer of new ordinary shares (“New Shares”) or new options (“Options”) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and
Slide 25: Appendices & Risks
25 For personal use only Appendices & Risks
Slide 26: Board & management
Board & management For personal use only DAVID WILLIAMS DR GEOFF CUMMING MAX JOHNSTON PHILIP POWELL Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Experienced biotechnology director and Healthcare and biotechnology director with Healthcare industry direct
Slide 27: Corporate history
Corporate history For personal use only Transformed from single-asset medtech to multi-asset biotech with next generation exosome platform < 2019 2020 2021 2022 2023 2024 University of Queensland SubB2M/CA15-3 test detects 19% SubB2M test Proof of Concept High-Throughput EXO-NET system collaboration
Slide 28: EXO-NET | Customers and capabilities
EXO-NET | Customers and capabilities For personal use only Generating revenue from EXO-NET product sales and services directly and via global partners Global EXO-NET supply & distribution agreement with Intending to out-license EXO-NET for commercial Promega Corporation expected to diagnostic applic
Slide 29: EXO-NET | Competitor comparison to other exosome isolation methods
EXO-NET | Competitor comparison to other exosome isolation methods For personal use only EXO-NET Method Immuno- Phospholipid- Size Ultra- Charge Precipitation Advantage affinity affinity Exclusion centrifugation Speed +++ +++ +++ ++ +++ + Cost-Effectivness +++ +++ ++ ++ ++ ++ Scalability High High H
Slide 30: Market Potential for Breast and Ovarian Cancer diagnostics
Market Potential for Breast and Ovarian Cancer diagnostics For personal use only Breast cancer diagnostics market Key Assumptions Relevant population Total Addressable Market (US$) Eligible Laboratory Test Selling Price (US$) $150 2 Prevalence Screening Screening 4 Market Population Incidence 2 3 3
Slide 31: Diagnostic deals & financings for liquid biopsy platforms
Diagnostic deals & financings for liquid biopsy platforms For personal use only Acquiror / Licensee Target / Licensor Date Type Deal Size (USD) Indication US$300m upfront plus 2023 Acquisition future performance milestones ctDNA liquid biopsy technology platform of up to $150m US$450m upfront plus 2
Slide 32: Therapeutic deals for exosome & cell therapies
Therapeutic deals for exosome & cell therapies For personal use only Acquiror / Licensee Target / Licensor Date Type Deal Size (USD) Indication / Clinical Stage US$1.2b incl. $1,000m upfront and $200m in Next-gen autologous CAR-T platform with Phase 2023 Acquisition milestones 1b oncology & autoimmu
Slide 33: Key Risks
Key Risks For personal use only This section includes details of the key risks attaching to an investment in INOVIQ securities. These risks may affect the future operating and financial performance of INOVIQ and the value of INOVIQ securities. Before deciding whether to invest in INOVIQ securities,
Slide 34: Key Risks (cont.)
Key Risks (cont.) For personal use only SPECIFIC RISK DESCRIPTION There are general risks associated with investments in equity capital such as INOVIQ securities. The trading price of INOVIQ securities may fluctuate with movements in equity capital markets in Australia and internationally. There is
Slide 35: Key Risks (cont.)
Key Risks (cont.) For personal use only SPECIFIC RISK DESCRIPTION It is likely that INOVIQ will need to form marketing and/or product development alliances with third parties for INOVIQ products in countries which INOVIQ seeks to commercialise (subject to ongoing legal and regulatory compliance and
Slide 36: Key Risks (cont.)
Key Risks (cont.) For personal use only SPECIFIC RISK DESCRIPTION The diagnostic and therapeutic industry is regulated in Australia, the United States, Europe and other countries in which INOVIQ may conduct business operations or seek to commercialise its products. INOVIQ has not yet formally engage
Slide 37: Key Risks (cont.)
Key Risks (cont.) For personal use only GENERAL RISK DESCRIPTION INOVIQ securities are only listed on the securities exchange operated by ASX and will not be listed for trading on any other financial markets, other than Chi-X. There can be no guarantee that an active market in INOVIQ securities will
Slide 38: Key Risks (cont.)
Key Risks (cont.) For personal use only GENERAL RISK DESCRIPTION INOVIQ may be subject to significant unforeseen expenses or actions. This may include unplanned operating expenses, future legal actions or expenses in relation to future unforeseen events. Unforeseen expenses INOVIQ may become unable